<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027221</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACT2010</org_study_id>
    <nct_id>NCT01027221</nct_id>
  </id_info>
  <brief_title>Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer</brief_title>
  <acronym>IMPACT2010</acronym>
  <official_title>Randomised Phase I/II Trial in Order to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Neoadjuvant Low-Dose-Radiation Therapy in Primarily Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Principal purpose of the study is the determination of an active local external beam&#xD;
      radiotherapy dose leading to a maximum number of tumor infiltrating T-cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity</measure>
    <time_frame>1 year</time_frame>
    <description>Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control and recurrence patterns of pancreatic cancer relative to a standard as seen in historical controls</measure>
    <time_frame>5 years</time_frame>
    <description>local control and recurrence patterns of pancreatic cancer relative to a standard as seen in historical controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical morbidity in patients undergoing pancreatic resection who received this protocol treatment</measure>
    <time_frame>1 year</time_frame>
    <description>surgical morbidity in patients undergoing pancreatic resection who received this protocol treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequencies of tumor-reactive T-cells in blood and bone marrow</measure>
    <time_frame>2 years</time_frame>
    <description>frequencies of tumor-reactive T-cells in blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of migration-relevant adhesion molecules on tumor endothelial cells</measure>
    <time_frame>2 years</time_frame>
    <description>expression of migration-relevant adhesion molecules on tumor endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of proinflammatory cytokines and activation-dependent, immune-associated transcriptionally factors in tumors and blood</measure>
    <time_frame>2 years</time_frame>
    <description>expression of proinflammatory cytokines and activation-dependent, immune-associated transcriptionally factors in tumors and blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months</measure>
    <time_frame>3 years</time_frame>
    <description>quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Primarily Resectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>0</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>primarily resectable pancreatic cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,5 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant Radiation of 0,5 Gy two days before resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant Radiation of 2 Gy 2 days before resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant Radiation of 5 Gy 2 days before resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant photon radiation</intervention_name>
    <description>single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection</description>
    <arm_group_label>0,5 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant photon radiation</intervention_name>
    <description>single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection</description>
    <arm_group_label>2 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant photon radiation</intervention_name>
    <description>single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection</description>
    <arm_group_label>5 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radiological diagnosis of resectable pancreatic carcinoma is required prior to&#xD;
             treatment. Potentially resectable is defined as no extrapancreatic disease, no&#xD;
             evidence (on CT) of involvement of the celiac axis or superior mesenteric artery, no&#xD;
             evidence (on CT or MRI) of occlusion of the superior mesenteric vein or superior&#xD;
             mesenteric-portal venous confluence.&#xD;
&#xD;
          -  No evidence of metastatic disease as determined by chest CT scan, abdominal CT scan&#xD;
             (or MRI)&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA)- Performance status of 1 to 3&#xD;
&#xD;
          -  Women of child bearing potential must practice adequate contraception and refrain from&#xD;
             breast feeding. Female patients must have a negative pregnancy test within 7 days of&#xD;
             treatment&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Locally irresectable pancreatic cancer&#xD;
&#xD;
          -  distant metastases&#xD;
&#xD;
          -  medically unfit for surgery&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  prior chemotherapy or radiation treatment&#xD;
&#xD;
          -  Other serious uncontrolled medical conditions that the investigator feels might&#xD;
             compromise study participation&#xD;
&#xD;
          -  Unwillingness to participate or inability to comply with the protocol for the duration&#xD;
             of the study&#xD;
&#xD;
          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,&#xD;
             without complete recovery&#xD;
&#xD;
          -  Participation in other interventional trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter E. Huber, Prof. PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Cancer Research Centre and Clinic for Radiation Oncology of the University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for General, Visceral and Transplantation Surgery</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Cancer Research Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Dose Radiation</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>Immunostimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

